

CURRICULUM VITAE

Updated: 4/5/2017

Name: Roger Alan Rodby

Office Address: 1426 W. Washington Blvd.
Chicago, IL 60607

Education: University of Illinois, College of Medicine,
Doctor of Medicine: 8/78-6/82
Western Illinois University,
Bachelor of Science: 8/74-5/78

Post-Graduate Training: **Internship and Residency**
Internal Medicine: University of Medicine & Dentistry of New Jersey (UMDNJ)-Rutgers Medical School - now Robert Wood Johnson University Hospital (RWJUH): 7/82-7/85
Chief Resident: UMDNJ-Rutgers/RWJUH: 12/84-7/85
Fellowship:
Nephrology: Rush University Medical Center, Rush Medical College, Chicago, Illinois: 7/85-7/87

Specialty Board Certifications: American Board of Internal Medicine: **Internal Medicine:** 9/85
American Board of Internal Medicine: **Nephrology:** 11/88

Licensure: Medical License, State of New Jersey, No. 43684: 1/84
Medical License, State of Illinois, No. 036-070596: 7/85-present

Hospital Appointments: **Clinical Instructor:** Department of Medicine, Rush University Medical Center, Chicago, Illinois: 7/85-7/90
Assistant Attending: Department of Medicine, Rush University Medical Center, Chicago, Illinois: 7/90-3/07
Senior Attending: Department of Medicine, Rush University Medical Center, Chicago, Illinois: 3/07-present

Academic Appointments: **Clinical Instructor:** UMDNJ-Rutgers Medical School: 2/84-7/85
Assistant Professor: Rush Medical College, Chicago, Illinois: 8/89-9/95
Associate Professor: Rush Medical College, Chicago, Illinois: 9/95-7/09
Professor: Rush Medical College, Chicago, Illinois: 7/09-present

Other Appointments:

Fellowship Training Program Director: Nephrology, Rush University Medical Center, Chicago, Illinois: 1/00-present

Director of Inpatient Dialysis Activities, Rush University Medical Center, Chicago, Illinois: 7/90-present

RUMC Department of Medicine Education Coordinator for Medical Residents for Nephrology: 9/06-7/15

Collaborative Study Group:
 Executive Committee: 7/91-7/01, 7/13- present
 Board of Directors: 7/91-7/01, 7/13- present
 Clinical Management Committee: 7/96-06, Chair 7/14-present

Continuing Medical Education (CME) **Course Director:** Renal Biopsy Conference Grand Rounds: 7/00-present

Clinical Science Committee: American Society of Nephrology: 10/01-11/03

Team Nephrologist: Chicago Bulls: 1/05-present
Team Nephrologist: Chicago White Sox: 1/05-present

RUMC Medical Staff Executive Committee: 7/07-7/09
 Blue Ribbon Panel Judge for NephMadness: 2015, 2016, 2017
 American Society of Nephrology Abstract Reviewer: 2015

Medical Advisory Boards:

NxStage Medical Scientific Advisory Board for Critical Care Nephrology: 5/05-present
 National Kidney Foundation of Illinois Scientific Advisory Board: 1/11-present
 Baxter Healthcare Medical Affairs Renal Advisory Board: 12/11

Editorial Boards:

Seminars in Dialysis - Assistant Editor “Dialysis Rounds”: 2003-present
American Journal of Kidney Diseases – Editorial Board “In Practice” Advisory Group: 11/16-present
American Journal of Kidney Diseases – Editorial Board: Social Media Advisory Group – <https://ajkdblog.org/meet-the-team/> 9/16- present
Clinical Nephrology - Editorial Board “Neph Ed” Section

American Society of Nephrology Patient Q&A Community: Community Leader – 8/16-present
 ASN Media and Communications Committee – Member 1/17-present

American Society of Nephrology Board Review Course Faculty Presentations:

Respiratory Acidosis and Alkalosis: 8/13, 8/14
 Peritoneal Dialysis Infectious and Non-Infectious Complications 7/15
 Hemodialysis: “Board Questions” 7/15

National Kidney Foundation of Illinois Young Investigators Research Grant Program Committee – 11/16-present

Awards and Honors:**Highest Graduating Honors: Western Illinois University: 5/78**

Research Appointment: Argonne National Laboratories, Bile Acid Kinetics,
Biomedical Research Department: 6/77-8/77

Phi Eta Sigma, W.I.U. Freshman Honor Society: 12/74

Beta Beta Beta, W.I.U. Biology Honor Society: 3/76.

Phi Kappa Phi, W.I.U. Scholastic Honor Society: 5/76

Medical Residents Research Paper Contest, Second Place,
UMDNJ-Rutgers: 5/82

Fellow: American College of Physicians (FACP): 7/90

Fellow: American Society of Nephrology (FASN): 11/11

**Rush University Medical Center Department of Internal Medicine
Teaching Award: 1993-94, 1997-98****Alpha Omega Alpha Honor Medical Society**

Best Doctors[®]: 1998, 2001, 2003, 2005, 2007, 2009, 2011, 2013, 2014, 2015
Castle Connolly - America's Top Doctors[®]: 2010, 2011, 2012, 2013, 2014,
2015, 2016

Top Doctors in Chicago, *Chicago Magazine*, January 1997

Top Doctors in Chicago, *Chicago Magazine*, January 2012

Top Doctors in Chicago, *Chicago Magazine*, January 2014

Top Doctors in Chicago, *Chicago Magazine*, January 2016

Top Nephrologist in Illinois, International Association of Healthcare
Professionals (IAHCP) 2013-16

America's Top Physicians: 2003, 2005, 2006, 2007, 2008

The Best Doctors in America: Midwest Region, First Edition, 1996-1997

Chicago Area's Top Doctors: Chicago Consumer's Checkbook: 2003

America's Registry of Outstanding Professionals: 2007

American Registry Top Doctors: 2009

Consumer's Guide to Top Doctors: 2009

Chicago Super Doctors 2012, 2013

Who's Who ("Canterbury"): 2010-11

Who's Who ("The Global Directory of"): 2007-14

**Professional Society
Memberships:**

International Society of Nephrology: 1989-

American Society of Nephrology: 1989-

National Kidney Foundation: 1989-

International Society for Peritoneal Dialysis: 1990-

European Dialysis and Transplant Association 2008-

Journal Reviewer:

American Journal of Kidney Diseases (AJKD)
Archives of Internal Medicine
Journal of the American Medical Association (JAMA)
Diabetes Care
Kidney International (KI)
Journal of the American Society of Nephrology (JASN)
Clinical Journal of the American Society of Nephrology (CJASN)
Journal of Cardiovascular Pharmacology
Endocrine Practice
Pharmacoeconomics
Archives of Family Medicine
Critical Care Medicine
Journal of Diabetes and its Complications
The Journal of Rheumatology
Peritoneal Dialysis International (PDI)
Nephrology Dialysis and Transplantation (NDT)
Clinical Nephrology
Blood Purification

Invited Lectures:

The Clinical Use of Erythropoietin in the Treatment of the Anemia of Chronic Renal Failure. Grand Rounds: Edgewater Medical Center, Chicago, IL 9/89.

The Clinical Use of Erythropoietin. Grand Rounds: St. Mary of Nazareth Hospital, Chicago, IL 1/90.

Present State of the Multicenter Trial of ACE Inhibition in Diabetic Nephropathy, Non-enzymatic Protein Glycosylation and Diabetic Complications. Regional Meeting on Diabetic Nephropathy, Grenoble, France 6/90.

Diabetic Nephropathy-Current Issues & Therapy. Thirty-Third Professional Symposium of the American Diabetes Association, Chicago, IL 10/90.

Diabetic Nephropathy. Nephrology Grand Rounds: Christ Hospital, Oak Lawn, IL 11/90.

Management of Fluid and Electrolyte Problems in the Neurosurgical Patient. Chicago Neurosurgical Center Symposium: Internal Medicine Problems in the Neurosurgical Patient, Chicago, IL 11/91.

Diabetic Nephropathy: Early Detection and Intervention. Seventeenth Annual Public Conference of the American Diabetes Association, Northern Illinois Affiliate, Chicago, IL 4/92.

Management of Hypertension in the Person with Diabetes. New Horizons in Diabetes Management: Thirty-Fifth Professional Symposium of the American Diabetes Association, Oakbrook, IL 10/92.

Nephrology Considerations in Diabetes Care. Diabetes Symposium for Health Care Professionals. Humana Hospital, Hoffman Estates, IL 11/92.

Results of the Collaborative Study Group Study of ACE Inhibition in Diabetic Nephropathy. Symposium on Antihypertensive Therapy and Progression of Renal Insufficiency. Essen, West Germany 10/93.

Results of the Collaborative Study Group Study of ACE Inhibition in Diabetic Nephropathy. National Meeting of Nephrology, Acapulco, Mexico 12/93.

Diabetic Nephropathy: Role of ACE Inhibition. Medical Grand Rounds, Grant Hospital, Chicago, IL 12/93.

Management of Diabetic Nephropathy. 50th Annual Midwest Clinical Conference of the Chicago Medical Society, Chicago, IL 2/94.

The Effects of Angiotensin-Converting-Enzyme Inhibitors on Diabetic Nephropathy. Medical Grand Rounds, Lutheran General Hospital, Park Ridge, IL 2/94.

Results of the Collaborative Study Group Study of ACE Inhibition in Diabetic Nephropathy. Symposium on Diabetic Nephropathy, Lisbon, Portugal 2/94.

Invited Lectures: (cont.)

Stalling the Complications of Diabetes: Focus on Kidney Disease. Medical Grand Rounds, Illinois Masonic Medical Center, Chicago, IL 3/94.

The Study of the Effect of Intensity of Blood Pressure Management on the Progression of Type 1 Diabetic Nephropathy: Study design and baseline patient characteristics. Conference on Prevention of Progression in Chronic Renal Disease, National Institute of Health, Bethesda, MD 4/94.

New Dimensions in the Management of Diabetic Nephropathy. Cena Conferencia, San Juan, Puerto Rico 4/94.

New Insights into the Prevention of Kidney Disease. 19th Public Conference for Persons with Diabetes and Their Families, River Grove, IL 4/94.

The Effects of Angiotensin-Converting-Enzyme Inhibitors on Diabetic Nephropathy. Medical Grand Rounds, Hennepin County Medical Center, Minneapolis, MN 4/94.

Therapeutic Interventions in Diabetic Nephropathy. Symposium on the Therapeutic Management of Risk Factors in Cardiovascular Disease, Cancun, Mexico 5/94.

Diabetic Nephropathy. Medical Grand Rounds, Swedish Covenant Hospital, Chicago, IL 6/94.

Stalling the Complications of Diabetes: Focus on Kidney Disease. Medical Grand Rounds, University of NV Washoe Medical Center, Reno, NV 6/94.

Challenges in the Management of Diabetes, A Symposium: Diabetic Nephropathy: A Look at Risk Factors, Preventive Measures and Interventional Treatment Options for the Patient with Early Nephropathy. Kansas City, MO 10/94.

Chaired Session of Oral Abstract Presentations on Diabetic Nephropathy: 27th Annual Meeting of the American Society of Nephrology. Orlando, FL 10/94.

The Medical and Pharmacoeconomic Implications of ACE inhibition for Diabetic Nephropathy: Cardiovascular Disease Symposium. San Francisco, CA 6/95.

Diabetic Nephropathy: Preventing Diabetes and its Complications: The Fourth Annual Becton Dickinson JDF Conference. Franklin Lakes, NJ 6/95.

Diabetic Nephropathy. Medical Grand Rounds, Greater Baltimore Medical Center, Baltimore, MD 10/95.

Advanced Glycosylation End-Products and the Complications of Diabetes. Symposium on Cardiovascular Disease in Diabetes. San Diego, CA 2/96.

The Pharmacoeconomics of Captopril in Diabetic Nephropathy. Conference on Diabetes and its Complications. Zeist, Netherlands 3/96.

Advanced Glycosylation End-Products and the Complications of Diabetes. Symposium on Cardiovascular Disease in Diabetes. Orlando, FL 4/96.

Invited Lectures: (cont.)

Effects of BP-level During ACE-inhibition on Renal Function in IDDM Patients. Third International Symposium on Proteinuria and Progressive Renal Disease. Amsterdam, Netherlands 6/96.

Systemic Lupus Erythematosus and End-Stage Renal Disease. Short Course: Lupus Nephritis. The 29th Annual Meeting of the American Society of Nephrology, New Orleans, LA 11/96.

American College of Physicians MKSAP 10 Review Course: Nephrology. Chicago, IL 11/96.

Slowing Down the Progression of Renal Insufficiency: Role of Diet and Pharmacology. Complications in Renal Failure. Dompé Biotec in Nefrologia. Chicago, IL 9/00.

Renoprotection: Can ESRD be avoided? Medical Grand Rounds. Rush University Medical Center. Chicago, IL 7/02.

AVVH: A New Model for Continuous Renal Replacement Therapy. NxStage Conference, ASN, San Diego, CA, 11/03.

Pharmacoeconomic Challenges in the Management of Hypertension. Symposium for 16th Annual meeting of the Academy of Managed Care Pharmacy, San Francisco, CA, 4/04.

Pharmacoeconomics of Prevention: IRMA2 and IDNT: International Symposium on Albuminuria: The Role of Albuminuria in Health and Disease: Predicting Outcomes and Targets for Therapy. New York, NY, 5/04.

What therapy to deliver when CVVH is not practical: Accelerated hemofiltration in the ICU. NxStage Conference, ASN, Philadelphia, PA, 11/05

Acute Renal Failure: “The more things change the more they stay the same”. Medical Grand Rounds. Rush University Medical Center. Chicago, IL 8/06.

Gadolinium Toxicity in renal disease: “Chicken Little” or “A Wolf in Sheep’s Clothing”? Medical Grand Rounds. Rush University Medical Center. Chicago, IL 5/07.

Gadolinium vs Iodinated Contrast: Comparison of Nephrotoxicity. Session on *Newer Iatrogenic Renal Disorders*. The American Society of Nephrology Renal Week 2007, San Francisco, CA, 11/07.

Risk-benefit of Gadolinium vs Iodinated Contrast in CKD. Spring 08 Clinical Meetings of the National Kidney Foundation, Dallas, TX, 4/08.

CRRT in the ICU: Keeping Your Options Open. Presbyterian Healthcare Hospital, Charlotte, NC, 6/09

AVVH, an alternative to CRRT in the ICU. East Carolina University Medical Center, Raleigh, NC, 6/09

The Success and Failure of Hemodialysis: Time to go “Back to the Future”. Medical Grand Rounds. Rush University Medical Center. Chicago, IL 2/10.

Invited Lectures: (cont.)

Nephrogenic Systemic Fibrosis: 3 Years Later. Medical Grand Rounds. Rush University Medical Center. Chicago, IL 9/10.

Nephrogenic Systemic Fibrosis: Contrasting Opinions on the Risk of Gadolinium. Medical Grand Rounds. Stroger Hospital of Cook County. Chicago, IL 1/12.

The Changing Face of CRRT: The 18th International Conference on Continuous Renal Replacement Therapies. San Diego, CA, 2/13.

Use of RRT for Metformin Toxicity and Associated Lactic Acidosis. Session: Extracorporeal Therapies for Intoxications and Drug Overdoses. The 48th Annual Meeting of the American Society of Nephrology, Philadelphia, PA, 11/14.

PUBLICATIONS:

Series Editor,
 “Dialysis Rounds”
Seminars in Dialysis

Piraino B: **Peritoneal dialysis catheter replacement: "Save the patient and not the catheter"**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2003;16:72-75.

Mir S, Serdaroglu E: **An elevated hemidiaphragm three months after internal jugular vein hemodialysis catheter placement**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2003;16:281-283.

Pollack CA: **Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2003;16:406-410.

Sinsakul M, Ali A: **Radioactive I¹³¹ usage in end-stage renal disease: Nightmare or nuisance?** A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2004;17:53-56.

Bellucci A: **Shortness of breath and abdominal pain within minutes of starting hemodialysis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2004;17:417-421.

Chang CS, Thajeb P, Chen H, Wu C: **Mycotic aneurysms and death in a hemodialysis patient**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2005;18:345-348.

Brucculeri M, Cheigh J, Bauer G, Serur D: **Long term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2005;18:431-434.

Guo PYF, Storsley LJ, Finkle SN: **Severe lactic acidosis treated with prolonged hemodialysis: Recovery after massive overdoses of metformin**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2006;19:80-83.

Schmiege LM, Wolf DA: **A case of fatal cardiac tamponade during hemodialysis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2006;19:434-437.

Lazar ES, Stankus N: **Cinacalcet induced hungry bone syndrome**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2007;20:83-85.

Pauly RP, Sood MM, Chan CT: **Management of refractory ascites using nocturnal home hemodialysis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2008;21:367-370.

Ryali ME, Whittier WL: **Bullous skin lesions in a patient undergoing chronic hemodialysis**. A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2010;23:83-87.

García-García P, Rivero A, del Castillo N, Jarque A, Getino MA, García-Pérez J, Navarro-González JF: **Infectious spondylodiscitis in hemodialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. Semin Dial 2010;23:619-626.

**Section Editor,
“Dialysis Rounds”
Seminars in Dialysis (cont.):**

Volpini K, Kinonen C: **Abdominal catastrophe in a 43 year-old female with end stage renal disease**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2011;24:79-82.

Patel UO, Fox SR, Moy JN, Korbet SM: **Pruritic rash and eosinophilia in a patient receiving peritoneal dialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2011;24:338-340.

Tapawan K, Chen E, Selk N, Hong E, Virmani S, Balk R: **A large pleural effusion in a patient receiving peritoneal dialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2011;24:560-563.

Wendland EM, Kaplan AA: **A proposed approach to the dialysis prescription in severely hyponatremic patients with end-stage renal disease**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2011;25:82-85.

Yan J, Ramanathan V: **Severe encephalopathy following cerebral angiogram in a patient with end-stage renal disease**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2013;26:203-207.

Patel C, Monga D, Alexander M, Magoon S, Bernstein D, Wagner JD, Mattana J: **Spontaneous clearance of hepatitis B surface antigenemia after long-term hemodialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2014;27:57-59.

Singh T, Hallows KR: **Hemodialysis for the treatment of severe accidental hypothermia**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2014;27:295-297.

Mehotra A, Tan JA, Ames SA: **“Out of sight out of mind”: The failed renal allograft as a cause of ESA resistance**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2015;28:530-532.

Aziz N, Luna C, Mirza F, Tobin M: **Anaphylactic shock at the end of hemodialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2015;28:661-664.

Sayed K, Murdakes C, Spec A, Gashti C: **Anaphylactic shock at the beginning of hemodialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2016;29:81-84.

Bansal AD, Negoianu D, and Warburton KM: **An unusual yet “Mg”nificent indication for hemodialysis**, A Dialysis Case Presentation and Discussion, Edited by **Roger A. Rodby**. *Semin Dial* 2016;29:247-250.

***Seminars in Dialysis*
Special Edition 1**

Guest Editors **Roger Rodby** and Mark Perazella. **Curbside Consultations: Questions and Answers on Dialysis**: 50 articles. *Semin Dial* 2011;24:364-451.

Special Edition 2

Guest Editors **Roger Rodby** and Mark Perazella. **Dialysis therapies and more: Things you should know**: 24 articles. *Semin Dial* 2014;27:221-324.

Special Edition 3

Guest Editors **Roger Rodby** and Mark Perazella. **Mistakes We Make in Dialysis**: 24 articles, *Semin Dial* 2016;29:258-325.

PUBLICATIONS:**Book Chapters:**

Rodby RA, Korbet SM: Causes, diagnosis, and treatment of peritoneal membrane failure. In Principles and Practice of Dialysis, Henrich WL (ed), Baltimore, Williams & Wilkens, 1994, Chapter 11: pp 130-147.

Rodby RA: Acute Renal Failure. In Quick Reference to Internal Medicine, Bone R (ed), New York, Igaku-Shoin, 1994, Chapter 85: pp 1105-1114.

Rodby RA: Hyponatremia. In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 521-531.

Rodby RA, Wester CW: Polyuria. In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 531-538.

Rodby RA: Metabolic Acidosis. In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 538-557.

Rodby RA, Wester CW: Acute Renal Failure. In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 557-568.

Wester CW, **Rodby RA: The Nephrotic Syndrome.** In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 568-576.

Wester CW, **Rodby RA: The Nephritic Syndrome.** In Diagnostic Strategies for Internal Medicine, A Case Based Approach, Grodzin CJ, Schwartz S, and Bone RC (eds), St. Louis, Mosby, 1996, pp 576-587.

Rodby RA, Rohde R, Mulcahy WS, Lewis EJ, on behalf of the Collaborative Study Group: Effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: Study design and patient characteristics. In Ace Inhibition and Renoprotection, Cooper ME, Remuzzi G (eds), Haslemere UK, Euromed Communications Ltd., 1997, pp 53-62.

Korbet SM, **Rodby RA: Causes, diagnosis, and treatment of peritoneal membrane failure.** In Principles and Practice of Dialysis, 2nd Edition, Henrich WL (ed), Baltimore, Williams & Wilkens, 1999, Chapter 13: pp 185-209.

Rodby RA, Lewis EJ: Type II Diabetic Nephropathy. In the International Handbook on Renal Disease, Brenner BM, Kurokawa K (eds), Haslemere UK, Euromed Communications Ltd. 1999, Chapter 4: pp 41-51.

Korbet SM, **Rodby RA: Causes, diagnosis, and treatment of peritoneal membrane failure.** In Principles and Practice of Dialysis, 3rd Edition, Henrich WL (ed), Baltimore, Lippincott Williams & Wilkens, 2004, Chapter 15: pp 206-226.

PUBLICATIONS:
Journal Publications:

Rodby RA, Korbet SM, Lewis EJ: Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis. Am J Med 1987; 83:613-618.

Lemann J, Doumas BT, Sasse EA, and the **Collaborative Study Group** of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy: **Diabetic nephropathy: Urinary albumin or total protein?** Ann Intern Med 1989;111:343-344.

Rodby RA: Management of the systemic lupus erythematosus patient with end-stage renal disease. Semin Dial 1989;2:180-185.

Schwartz MM, Lan S, Bonsib SM, Gephardt GN, Sharma HM, and The Lupus Nephritis **Collaborative Study Group: Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis.** Am J Kid Dis 1989;13:273-283.

Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, and The Lupus Nephritis **Collaborative Study Group: Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis.** Kidney Int 1989;36:891-896.

Rodby RA: Baby poop peritonitis. Periton Dial Inter 1990;10:99-100.

Lemann J, Bidani AK, Bain RP, Lewis EJ, Rohde RD, and the **Collaborative Study Group** of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy: **Use of the serum creatinine to estimate GFR in health and early diabetic nephropathy.** Am J Kid Dis 1990;16:236-243.

Dodhia N, **Rodby RA**, Jensik SC, Korbet SM: **Renal transplant arterial thrombosis: Association with cyclosporine.** Am J Kid Dis 1991;17: 532-536.

Pohl MA, Lan S, Berl T, and The Lupus Nephritis **Collaborative Study Group: Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis.** Ann Intern Med 1991;114:924-929.

Rodby RA, Trenholme GM: Vaccination of the dialysis patient. Semin Dial 1991;4:102-105.

Rodby RA, Glick EJ: Agrobacterium radiobacter peritonitis in two patients on chronic peritoneal dialysis. Am J Kid Dis 1991;18:402-405.

Ricker DM, Hebert LA, Rohde R, Sedmark D, Lewis EJ, Clough JD, and The Lupus Nephritis **Collaborative Study Group: Serum C3 levels are diagnostically more sensitive and specific for SLE activity than are serum C4 levels.** Am J Kid Dis 1991;18:678-685.

Rodby RA, Tyszka TS, Williams JW: Reversal of cardiac dysfunction secondary to type 1 primary hyperoxaluria after combined liver-kidney transplantation. Am J Med 1991;90:498-504.

Journal Publications (cont.):

Levey AS, Lan S, Corwin H, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, and The Lupus Nephritis **Collaborative Study Group**: **Progression and remission of renal disease in the lupus nephritis collaborative study: Results of treatment with prednisone and short-term oral cyclophosphamide.** Ann Intern Med 1992;116:114-123.

Lewis EJ, Hunsicker LG, Lan S, Rohde R, Lachin J, For The Lupus Nephritis **Collaborative Study Group**. **A controlled trial of plasmapheresis therapy in severe lupus nephritis.** NEJM 1992;326:1373-1379.

Schwartz MM, Lan S, Bernstein J, Hill GS, Holley K, Lewis EJ, and The Lupus Nephritis **Collaborative Study Group**. **Role of pathology indices in the management of severe lupus glomerulonephritis.** Kidney Int 1992;42:743-748.

Rodby RA, Schwartz MM: Clinicopathological Conference: Proteinuria, hematuria, hypertension and decreased renal function in a patient with diabetes for 9 years. Am J Kid Dis 1992;20:658-667.

Rodby RA, Ali AA, Rohde RD, Lewis EJ, and the Collaborative Study Group for the Study of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy: **Renal scanning TcDTPA GFR determination compared to iothalamate GFR in diabetics.** Am J Kid Dis 1992;20:569-573.

Bain R, Rohde R, Hunsicker LG, McGill J, Kobrin S, Lewis EJ, and the **Collaborative Study Group** for the Study of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy: **A controlled trial of angiotensin-converting enzyme inhibition in type 1 diabetic nephropathy: Study design and patient characteristics.** J Am Soc Nephrol 1992;3:S97-S103.

Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, **Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: A circulating marker of advanced glycosylation.** Science 1992;258:651-653.

Schwartz MM, Shu-Ping L, Bernstein J, Hill GS, Holley K, Lewis EJ, and the Lupus Nephritis **Collaborative Study Group**: **Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis.** Am J Kid Dis 1993;21:374-377.

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, and the **Collaborative Study Group** for the Study of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy: **The effect of angiotensin converting enzyme inhibition on diabetic nephropathy.** NEJM 1993;329:1456-1462.

Burstein DM, **Rodby RA: Membranoproliferative glomerulonephritis (MPGN) associated with hepatitis C virus infection.** J Am Soc Nephrol 1993;4:1288-1293.

Breyer JA, Hunsicker LG, Bain RP, Lewis EJ, and the **Collaborative Study Group**: **Angiotensin converting enzyme inhibition in diabetic nephropathy.** Kidney Int 1994;45:S156-S160.

Journal Publications (cont.):

Rodby R, Vonesh E, Korbet S: Blood pressures in hemodialysis and peritoneal dialysis using ambulatory BP monitoring. Am J Kid Dis 1994;23:401-411.

Korbet SM, **Rodby RA: Peritoneal membrane failure: Differential diagnosis, evaluation, and treatment.** Semin Dial 1994;7:128-137.

Rodby, RA: Captopril for diabetic nephropathy. The Medical Letter 1994;36:46-47.

Subbaiah PV, **Rodby RA: Abnormal acyltransferase activities and accelerated cholesterol ester transfer in the nephrotic syndrome.** Metabolism 1994;43:1126-1133.

Solmos GR, Ali A, **Rodby RA, Fordham EW: Rapid reversal of bone scan abnormalities in a patient with type 1 primary hyperoxaluria and oxalosis.** Clin Nucl Med 1994;19:769-772.

Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ, for the **Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes.** Kidney Int 1994;46:1688-1693.

Rodby RA, Schwartz MM: Clinicopathological Conference: Nephrotic syndrome in a patient with unilateral renal dysplasia. Am J Kid Dis 1995;25:88-95.

Korbet SM, Casey C, **Rodby RA, Williams JW: The use of continuous arteriovenous hemofiltration in orthotopic liver transplantation.** [letter] Clin Nephrol 1995;43:134-136.

Rodby RA: Diabetic nephropathy: New advances in therapy. Res & Staff Phys 1995;41:13-20.

Rodby RA, Rohde R, Evans J, Bain R, Mulcahy WS, Lewis EJ, and the Collaborative Study Group: The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: Study design and baseline patient characteristics. J Am Soc Nephrol 1995;5:1775-1782.

Conlon P, Butterfly D, Albers F, **Rodby R, Gunnells JC, Howell D: Clinical and pathologic features of familial focal segmental glomerulosclerosis.** Am J Kid Dis 1995;26:34-40.

Rodby RA: Current issues in diabetic nephropathy. Cardiotopics, MediMedia Communications, Hong Kong 1995.

Rodby RA: Nonuremic uses for dialysis. Semin Dial 1995;8:314-319.

Rodby RA, Rohde RD, Sharon Z, Pohl M, Bain RP, Lewis EJ for the Collaborative Study Group: The urine protein to creatinine ratio as a predictor of 24 -hour urine protein excretion in type 1 diabetic patients with nephropathy. Am J Kid Dis 1995;26:904-910.

Rodby RA, Firanek CA, Cheng YG, Korbet SM: The reproducibility of studies of peritoneal dialysis adequacy. Kidney Int 1996;50:267-271.

Journal Publications (cont.):

Rodby R, Firth L, Lewis E: An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996;19:1051-1061.

Sloan RP, Schwartz MM, Korbet SM, Borok RZ, and the Lupus Nephritis Collaborative Study Group: **Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis.** J Am Soc Neph 1996;7:299-305.

Rodby RA, Lewis EJ: ACE inhibition in normotensive diabetic patients: Economic Implications. PharmacoEconomics 1996;10:315-320.

Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis EJ, Cooper M, McGill J, Berl T, and the Collaborative Study Group: **Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy.** Kidney Int 1996;50:1651-1658.

Rodby RA: Protecting those fabulous filters. Diabetes Forecast 1997, March Issue: 32-36.

Rodby RA: Type II diabetic nephropathy: Its clinical course and therapeutic implications. Semin Nephrol 1997;17:132-147.

Rodby RA: Economic implications of ACE inhibition for diabetic nephropathy. ACE Inhibition 1997;6:18-19.

Rodby RA: Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacologic blockade of the renin-angiotensin system. Nephrology Dialysis Transplantation 1997;12:1095-1096.

Rydel JJ, Rodby RA: **An 18-year-old man with Goodpasture's syndrome and ANCA-negative central nervous system vasculitis.** Am J Kid Dis 1998;31:345-349.

Weiss MA, Rodby RA, Justice AC, Hricik DE, and the Collaborative Study Group: **Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy.** Kidney Int 1998;54:193-202.

Rodby RA: Hemofiltration for SIRS: Bloodletting, twentieth century style? Crit Care Med 1998;26:1940-1942.

Schwartz ME, Lewis EJ, Leonard-Martin T, Breyer Lewis J, Battle D, and the Collaborative Study Group: **Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy.** Nephrol Dial and Transplant 1998;13:2547-2552.

Conlon PJ, Lynn K, Winn M, Quarles LD, Membe ML, Pericak-Vance M, Speer M, Howell DN, on behalf of the International Collaborative Group for the Study of Familial Focal and Segmental Glomerulosclerosis: **Spectrum of disease in familial focal and segmental glomerulosclerosis.** Kidney Int 1999;56:1863-1871.

Rodby R, Firanek C: Re-evaluation of solute transport groups using the peritoneal equilibration test. Periton Dial Inter 1999;19:438-441.

Lewis J, Berl T, Bain R, Rohde R, Lewis E, and the Collaborative Study Group: **Effect of intensive blood pressure control on the course of type I diabetic nephropathy.** Am J Kid Dis 1999;34:809-817.

Journal Publications (cont.):

Sharma K, Eltayeb B, McGowan T, Dunn S, Alzahabi B, Rohde R, Ziyadeh F, Lewis E, and the **Collaborative Study Group: Captopril induced reduction of serum levels of transforming growth factor- β 1 correlates with long-term renoprotection in insulin dependent diabetic patients.** Am J Kid Dis 1999;34:818-823.

Rodby RA, Rohde RD, Clark WR, Hunsicker LG, Anzalone DA, Lewis EJ for the Collaborative Study Group: **The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics.** Nephrol Dial and Transplant 2000;15:487-497.

Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, for the **Collaborative Study Group: Factors predictive of outcome in severe lupus nephritis.** Am J Kid Dis 2000;35:904-914.

White KE, Bilous RW, for the **Collaborative Study Group: Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease.** JASN 2000;11:1667-1673.

Nicholas JJ, Khanna P, Baldwin DB, Merkel F, **Rodby R**, Jensik S: **Amputations associated with arteriovenous access.** Am J of Phy Med & Rehab 2000;79(2):180-183.

Lewis EJ, Hunsicker LG, **Rodby RA**, for the Collaborative Study Group: **A clinical trial in type 2 diabetic nephropathy.** Am J Kid Dis 2001;38(4)suppl1:S191-194.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the **Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.** NEJM 2001;345(12):851-860.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG for the **Collaborative Study Group: Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy.** Diabetes Care 2002;25:2037-2041.

Rodby RA, Firanek CA: Aliquot vs batch sampling methods for measurements of peritoneal dialysis adequacy in patients receiving CAPD. Periton Dial Inter 2003;23:87-89.

Rodby RA, Chiou C, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, and Lewis EJ, for the Collaborative Study Group: The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetes. Clinical Therapeutics 2003;25:2102-2119.

Palmer AJ, Annemans L, Roze S, Lamotte M, **Rodby RA**, Cordonnier D for the Collaborative Study Group: **An Economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: Cost-effectiveness of irbesartan in diabetic nephropathy trial (IDNT) in the Belgian and French settings.** Nephrol Dial Transplant 2003;18:2059-2066.

Coyle D, **Rodby RA: Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.** Can J Cardiology 2004;20:71-79.

Journal Publications (cont.):

Palmer AJ, Annemans L, Roze S, Lamotte M, LaPuerto P, Gabriel S, Carita P, **Rodby RA**, de Zeeuw D, Parving HH. **Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACEi, other ARB and dihydropyridine CCB) or late irbesartan treatment in patients with type 2 diabetes, hypertension and renal disease.** Diabetes Care 2004;27:1897-1903.

Rodby RA. Pharmacoeconomic challenges in the management of diabetic nephropathy. J Managed Care Pharm 2004;10:S6-11.

Palmer AJ, **Rodby RA.** **Health economic studies assessing irbesartan use with hypertension, type 2 diabetes and microalbuminuria.** Kidney Int. 2004;66:S118-S120.

Palmer AJ, Annemans L, Roze S, Lamotte M, **Rodby RA**, Ritz E, for the Collaborative Study Group: **Gesundheitsökonomische Aspekte der Anwendung von irbesartan bei Patienten mit typ-2-Diabetes, Nephropathie und Hypertonie in Deutschland (Health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in Germany).** Dtsch Med Wochenschr 2004;29:13-18.

Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, **Rodby R**, de Zeeuw D, Parving H, De Alvaro F. **Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.** Kidney Int 2005;67:S52-S54.

Palmer AJ, Annemans L, Roze S, Lamotte M, Berto Ravera M, **Rodby RA.** **Costo-efficacia di irbesartan in pazienti con diabete di tipo 2, ipertensione e nefropatia: prospettiva italiana.** Pharmacoeconomics-Italian Research Articles 2005;7(1):41-55.

Pohl MA, Blumenthal S, Cordonnier DJ, DeAlvaro F, DeFerrari G, Eisner G, Esmatjes E, Gilbert R, Hunsicker L, Lopes de Faria J, Mangili R, Moore J, Reisin E, Ritz E, Scherthaner G, Spitalowitz S, Tindall H, **Rodby R**, Lewis EJ for the Collaborative Study Group. **Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial (IDNT): Clinical implications and limitations.** J Am Soc Neph 2005;16:3027-3037.

Rodby RA, Bengt Jönsson: Economic value of irbesartan in hypertension in patients with diabetes in the United States and Europe. The value of irbesartan: From clinical efficacy to cost effectiveness: Sanofi-Aventis Ref# HEE.IRB.05.07.01, 2006.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, **Rodby RA**, de Zeeuw D, Parving HH, Laville M: **A French cost-consequence analysis of the renoprotective benefits of irbesartan in diabetes and hypertension.** Curr Med Res Opin 2006;22:2095-2100.

Palmer AJ, Roze S, **Rodby RA**, Valentine WJ, Ritz E, Lehnert: **Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy.** Dtsch Med Wochenschr 2006; 131:1721-1726.

Rodby RA: Preventing complications of radiographic contrast media: Is there a role for dialysis? Semin Dial 2007;20(1):19-23.

Journal Publications (cont.):

Perazella MA, Rodby RA: **Gadolinium use in patients with kidney disease: A cause for concern?** *Semin Dial* 2007;20(3):1-4.

Perazella MA, Rodby RA: **Nephrogenic systemic fibrosis: A devastating complication of gadolinium in patients with severe renal impairment.** *Vasc Dis Management* 2007;4(2):45-47.

Perazella MA, Rodby RA: **Gadolinium induced nephrogenic systemic fibrosis in patients with kidney disease.** *Am J Med* 2007;120:561-562.

Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, Cotret P, Chen R, Palmer A: **Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: A Canadian perspective.** *Clinical Therapeutics* 2007;7:1508-1523.

Rodby RA: **The case for increased renal replacement therapy dosing in ICU patients with acute renal failure: Re-examining Current Evidence.** Newsletter, NxStage Medical, Inc, Lawrence, MA. 8/07.

Sinsakul, MS, Sika M, Rodby RA, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Harris R, Lewis J: **A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.** *Am J Kidney Dis* 2007;50:946-951.

Perazella M, Rodby R: **Nephrogenic systemic fibrosis, gadolinium-based contrast exposure, and liver disease.** *Letter to Editor*, *Am J Med* 2008;121:e13.

Rodby RA: **Dialytic Therapies to Prevent NSF following Gadolinium Exposure in High-risk Patients.** *Semin Dial* 2008;21(2):145-149.

Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA: **A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.** *Nephrol Dial Transplant* 2008;23:1216-1223.

Gashti C, Salcedo S, Robinson V, Rodby R: **Accelerated veno-venous hemofiltration (AVVH): An alternative to traditional continuous renal replacement therapy (CRRT).** *Am J Kidney Dis* 2008;51:804-810.

Levey, AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman H, Kusek J, Eggers P, Van Lente F, Greene T, Coresh J for the CKD-EPI: **A new equation to estimate glomerular filtration rate.** *Ann Intern Med* 2009;150:604-612.

Kropp J, Sinsakul M, Butsch J, Rodby R: **Laparoscopy in the early diagnosis and management of sclerosing encapsulating peritonitis.** *Semin Dial* 2009;22:304-307.

Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang Y, Schmid CH, Levey AS for the Chronic Disease Epidemiology Collaboration (CKD-EPI): **Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.** *Am J Kidney Dis* 2009;54:33-42.

Jolly M, Pickard AS, Mikolaitis RA, Rodby RA, Sequeira W, Block JA: **Lupus QoL-US: Benchmarks for U.S. patients with systemic lupus erythematosus.** *J Rheumatol* 2010;37:1828-1833.

Journal Publications (cont.):

Ix JH, Wassel CL, Stevens L, Beck GJ, Froissart M, Navis G, **Rodby R**, Torres VE, Zhang Y, Greene T, Levey A: **Equations to estimate creatinine excretion rate: The CKD epidemiology collaboration.** Clin J Am Soc Nephrol 2011;6:184-191.

Selk N, **Rodby RA**: **Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy.** Semin Dial 2011;24:85-88.

Rodby RA: **Can gadolinium be given safely to a patient on dialysis?** Semin Dial 2011;24:370-371.

Perazella MA, **Rodby RA**: **Common clinical quandaries encountered in dialysis and ESRD: Questions answered.** Semin Dial 2011;24:363.

Gashti CN, **Rodby RA**, Huang Z, Gao D, Zhang W: **Effects of high blood flow and high pre-dilution replacement fluid rates on small molecule clearances in hemofiltration.** Blood Purif 2011;32:266-270.

Inker IA, Schmidt CH, Tighiouart H, et al. **Estimating glomerular filtration rate from serum creatinine and cystatin C.** N Engl J Med 2012;367:20-29.

Padala S, Tighiouart H, Inker L, Contreras G, Beck GJ, Lewis J, Steffes M, **Rodby RA**, Schmid CH, Levey AS: **Accuracy of a glomerular filtration rate estimating equation over time in people with a wide range of kidney function.** Amer J Kid Dis 2012;60:217-224.

Jolly M, Pickard AS, Block J, Kumar R, Mikolaitis C, Wilke F, **Rodby R**, Fogg L, Sequeira W, Utset T, Cash T, Moldovan I, Katsaros E, Nicassio P, Ishimori M, Kosinsky M, Merrill J, Weisman M, Wallace D: **Disease specific patient reported outcome tools for systemic lupus erythematosus.** Semin Arth Rheum 2012;42:56-65.

Korbet SM, Lewis EJ for the **Collaborative Study Group**: **Severe lupus nephritis: the predictive value of a >50% reduction in proteinuria at 6 months.** Nephrol Dial Transplant 2013;28:2313-2318.

Birmingham DJ, Shidham G, Perna A, Fine D, Bissell M, **Rodby R**, Remuzzi G, Petri M, Hebert P, Rovin B, Hebert L: **Spot P/C ratio is more unreliable in estimating 24-hr proteinuria in lupus nephritis than in other forms of chronic glomerular disease.** Ann Rheum Dis 2014;73:475-476.

Rodby R, Perazella M: **Common clinical quandaries encountered by the nephrologist: More questions answered.** Semin Dial 2014;27:221-223.

Inker L, Levey A, Pandya K, Stoycheff N, Okparavero A, Greene T on behalf of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI): **Early change in proteinuria as a surrogate end point for kidney disease progression: An individual patient meta-analysis.** Am J Kidney Dis 2014;64:74-85.

Sinsakul M, **Rodby R**, Umanath K, Niecestro R, Dwyer J. **Ferric citrate spans mineral metabolism and anemia domains in ESRD: A review of efficacy and safety data.** Expert Rev Clin Pharmacol 2014;7:705-710.

Sahota S, **Rodby R**: **In-patient hemodialysis without anticoagulation in adults.** Clin Kidney J 2014;7:552-556.

Journal Publications (cont.):

Sahota S, **Rodby R**, Korbet S: **An elevated creatinine in a patient with normal renal function: The value of cystatin C.** Nephrology 2015;20:383-384.

Rodby R, Umanath K, Niecestro R, Jackson J, Sika M, Lewis J and Dwyer J, for the Collaborative Study Group: **Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.** Expert Rev Pharmacoecon Outcomes Res 2015;15:545-550.

Rodby RA: How does a patient's primary renal disease impact chronic dialysis management? Diseases treated with immunosuppressive agents. Semin Dial 2015;28:466-468.

Rodby R, Umanath K, Niecestro R, Bond, C, Sika M, Lewis J, Dwyer J, for the Collaborative Study Group: **Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data.** Drugs in R&D 2015;15:271-279.

Rodby R, Perazella M: **Mistakes we make in dialysis.** Semin Dial 2016;29 No 4:257.

Rodby RA: Timed urine collections for albumin and protein: "The king is dead, long live the king". Am J Kidney Dis 2016;68(6):836-838.

Rodby RA: The good news and the good news about the treatment of lupus nephritis. Submitted to AJKD on-line blog: <https://ajkdblog.org/>

Onkka P, **Rodby RA: When the HeRO becomes the villain.** Submitted to Seminars in Dialysis

Rodby RA: The long and winding road: What we think we know about the treatment of proliferative lupus nephritis. [AJKD online](#) Pending.

Rodby RA: The good news and the good news about the treatment of lupus nephritis. [AJKD online](#) Pending.

**Abstracts and
Presentations:**

Rodby R, Korbet SM, Lewis EJ: The persistence of clinical and serologic activity in systemic lupus erythematosus patients on chronic peritoneal dialysis. Presented at the 19th Annual Meeting of the American Society of Nephrology, December 1986, Washington, DC. *Kidney Int* 1987;31No.1:254.

Lacy CR, **Rodby RA**, Insel J, Gumprecht EC, Kostis JB: **Comparison of central and peripheral venous routes of medication administration during closed chest cardiopulmonary resuscitation in humans.** Presented at the 16th Annual Educational and Scientific Symposium of the Society of Critical Care Medicine, May 1987. *Crit Care Med* 1987;15No.4:369.

Rodby RA, Korbet SM, Lewis EJ: Chronic ambulatory peritoneal dialysis (CAPD) as an alternative to hemodialysis for patients with end-stage renal disease (ESRD) secondary to multiple myeloma (MM). *Kidney Int* 1989;35No.1:199.

Korbet SM, **Rodby RA**, Lewis EJ: **Anemia of chronic renal failure: A comparison of patients on ambulatory peritoneal dialysis (PD) vs hemodialysis (HD).** *Kidney Int* 1989;35No.1:196.

Dodhia N, **Rodby RA**, Jensik SC, Korbet SM: **Cyclosporin A associated renal allograft arterial thrombosis and the use of acetylsalicylic acid for prophylaxis.** *Kidney Int* 1990;37No.1:605.

Rodby RA, Ali A, Rohde RD, Bidani AK, Lewis EJ, and the Collaborative Study Group: **Renal scanning TcDTPA GFR determination compared to iothalamate clearance in diabetic patients.** Presented at the 23rd Annual Meeting of the American Society of Nephrology, December 1990, Washington, DC. *JASN* 1990;1No.4:340.

Subbaiah PV, **Rodby RA: Abnormalities in the synthesis and transfer of cholesterol esters in nephrotic syndrome.** Presented at the 23rd Annual Meeting of The American Society of Nephrology, December 1990, Washington, DC. *JASN* 1990;1No.4:343.

Dodhia N, **Rodby RA: Oxalate removal during continuous arterio-venous hemofiltration (CAVH) in a patient with type 1 hyperoxaluria, oxalosis and renal failure.** *JASN* 1990;1No.4:355.

Bagdade J, Ritter M, **Rodby R**, Thistlewaite R, Fellner S, Dunn F: **Insulin therapy pathologically alters cholesterol ester transfer (CET) in insulin dependent diabetes mellitus (IDDM).** Presented at the 64th Scientific Session of the American Heart Association, November 1991.

Foster P, Kluskens L, Sankary H, Moore L, **Rodby R**, Williams J: **Stepwise logistic regression analysis of fine needle aspirate cytology of renal allografts.** *JASN* 1991;2No.3:797.

Rodby R, Korbet S, Vonesh E: A comparison of blood pressure (BP) in peritoneal dialysis (PD) and hemodialysis (HD) patients using ambulatory blood pressure monitoring. Presented at the 13th Annual Conference on Peritoneal Dialysis, March 1993, San Diego, CA. *Periton Dial Inter* 1993;13:S80.

**Abstracts and
Presentations (cont.):**

Bucala R, Cerami A, Makita Z, Koschinsky T, Grundy S, **Rodby R**, Cartwright K, Vlassara H: **Inhibition of advanced glycosylation by aminoguanidine reduces plasma LDL levels in diabetes**. American Society of Clinical Investigation, April 1993.

Rodby RA, Rohde RD, Bain RP, Sharon Z, Pohl MA, Lewis EJ and the Collaborative Study Group: **The urine protein to creatinine ratio (P/C) as a predictor of 24-hour urine protein excretion (24UP) in type 1 diabetics with nephropathy**. JASN 1993;4No.3:308.

Breyer JA, McGill J, Nahman S, Lewis E, and the Collaborative Study Group: **Predictors of the rate of renal insufficiency in patients with insulin-dependent diabetes and overt nephropathy**. JASN 1993;4No.3:301.

Lewis EJ, Bain RP, Rohde RD, Hunsicker LG, and the Collaborative Study Group: **A controlled clinical trial of angiotensin-converting enzyme (ACE) inhibition in type 1 diabetic nephropathy**. JASN 1993;4No.3:305.

Hebert LA, Bain RP, Cattran D, Whittier F, Tolchin N, Rohde RD, Lewis EJ, and the Collaborative Study Group: **Remission of nephrotic-range proteinuria in type 1 diabetes: Experience of the NIH multicenter controlled trial of captopril therapy in diabetic nephropathy**. JASN 1993;4No.3:303.

Conlon P, Butterfly D, Albers F, **Rodby R**, Gunnells JC, Schwartz M, Howell D: **Clinical and pathologic features of familial focal segmental glomerulosclerosis (FSGS)**. Presented at the 27th Annual Meeting of the American Society of Nephrology, October 1994. JASN 1994;5No.3:644.

Rodby R, Rohde R, Evans J, Bain R, Mulcahy W, Lewis E, and the Collaborative Study Group: **Design and baseline characteristics of the study of the effect of intensity of blood pressure (BP) management on the progression of type 1 diabetic nephropathy**. JASN 1994;5No.3:382.

Rodby R, Firth L, Lewis E: **An economic analysis of captopril in the treatment of diabetic nephropathy**. Presented at the 27th Annual Meeting of the American Society of Nephrology, October 1994. JASN 1994;5No.3:382.

Moberly JB, Liu XQ, Buchanan LF, Zimmerman SW, **Rodby RA**, Fellner SK, Swartz RD, Bagdade JD: **Mode of insulin delivery, lipoprotein composition and cholesterol ester transfer in diabetic CAPD patients**. Presented at the 6th Asian-Pacific Congress of Nephrology, December 1995.

Rodby RA, Firanek CA, Cheng YG, Korbet SM: **The reproducibility of KT/V measurements**. Presented at the 16th Annual Conference on Peritoneal Dialysis, February 1996, Seattle, WA. Periton Dial Inter 1996;16Supp.2:S30.

Bagdade JD, Moberly JB, Liu XQ, Buchanan WF, **Rodby RA**, Ho T, Swartz R, Zimmerman SW: **Influence of route of insulin delivery on cholesterol ester (CE) transfer in diabetic ESRD patients**. Presented at the 16th Annual Conference on Peritoneal Dialysis, February 1996, Seattle, WA. Periton Dial Inter 1996;16Supp.2:S57.

**Abstracts and
Presentations (cont.):**

J.B. Moberly, J.D. Bagdade, **R. Rodby**, T. Ho, R. Swartz, S.W. Zimmerman and P. Alaupovic: **Influence of mode of dialysis and route of insulin delivery on plasma lipoproteins in diabetic ESRD patients.** Presented at the 8th International Congress on Nutrition and Metabolism in Renal Disease, October 1996.

Rodby RA, Firanek CA: A reevaluation of PET determined patient solute transport group classifications. Presented at the 29th Annual Meeting of the American Society of Nephrology, November 1996, New Orleans, LA. JASN 1996;7No.9:1433.

Rodby RA, Firanek CA: A comparison of body surface area (BSA) to peritoneal equilibration test (PET) determined solute transport in adults. JASN 1996;7No.9:1433.

Friedlander MA, **Rodby RA**, Justice AC, Hricik DE and the Collaborative Study Group (CSG): **Neopterin and free pentosidine as markers for progression of diabetic nephropathy.** Presented at the 30th Annual Meeting of the American Society of Nephrology, November 1997, San Antonio, TX. JASN 1997;8:112A.

Peano CA, Sarpolis AL, **Rodby RA: Potassium (K) balance in peritoneal dialysis (PD).** Presented at the 18th Annual Conference on Peritoneal Dialysis, February 1998, Nashville, TN. Periton Dial Inter 1998;18:S15.

Firanek C, **Rodby RA: Batch vs aliquot sampling for adequacy measurements.** Presented at the 18th Annual Conference on Peritoneal Dialysis, February 1998, Nashville, TN. Periton Dial Inter 1998;18:S44.

Chander N, Wozniak JA, **Rodby RA: The economic impact of increased usage of intravenous iron dextran (IVFe) and subcutaneous erythropoietin (SQ EPO) on the total cost of anemia treatment in hemodialysis (HD) patients (Pts).** Presented at the 31st Annual Meeting of the American Society of Nephrology, October 1998, Philadelphia, PA. JASN 1998;9:232A.

Sinsakul M, **Rodby, RA**, Rohde R, and Edmund Lewis, for the Collaborative Study Group. **Long-term clinical outcome differences between nodular and diffuse mesangial glomerulosclerosis in type II diabetic nephropathy.** Presented at the Clinical Nephrology Meetings of the National Kidney Foundation, April 2001, Miami, FL. Am J Kid Dis, 2001;37 No 4.

R. Rodby, L. Ruilope, L. Hunsicker and E. Lewis, for the Collaborative Study Group: **Results of the irbesartan type II diabetic nephropathy trial.** Presented at the European Society of Hypertension meeting, Milan, Italy June 2001.

Rodby R, Simon T, Chen R, L'italien G, Waldeck R, Yuan Y, Lewis E, for the Irbesartan in Diabetic Nephropathy Trial (IDNT) of the Collaborative Study Group: **An economic analysis of irbesartan in type II diabetic nephropathy.** Presented at the 4th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Cannes France, November 2001. Value in Health 2001;4:508-509.

**Abstracts and
Presentations (cont.):**

Rodby RA, Sengupta N, Simon T, Smitten A, Chiou CF, Borenstein J, Chen R, Lewis EJ for the Collaborative Study Group: **Cost-Effectiveness of irbesartan treatment in diabetic nephropathy**. Presented at the 62nd Scientific Sessions of the American Diabetes Association, June 2002, San Francisco, CA. Diabetes 2002;51:A281.

Rodby R, **Gilbert R**, for the Collaborative Study Group: **The presence of retinopathy is associated with poor renal and cardiovascular outcomes in type 2 diabetic nephropathy**. Presented at the 35th Annual Meeting of the American Society of Nephrology, November 2002, Philadelphia, PA. JASN 2002;13:644A.

Rodby R, et al, for the Collaborative Study Group: **Irbesartan is projected to save money while prolonging life in type 2 diabetic nephropathy: A pharmacoeconomic model of the irbesartan in diabetic nephropathy trial (IDNT)**. JASN 2002;13:687A.

Rodby R: **Adequacy is easier to achieve using Ccr/1.73m² compared to KT/Vurea in obese patients**. JASN 2002;13:726A.

Sinsakul M, Hayden M, Repetti C, **Rodby R**: **Cryoglobulinemic membranoproliferative glomerulonephritis associated with chronic Lyme disease**. JASN 2002;13:682A.

Palmer AJ, Annemans L, Roze S, Lamotte M, Guilhaume C, Gabriel S, Carita P, Chen R, Simon T, **Rodby R**, Cordonnier DJ: **The health-economic implications of the “Irbesartan in Diabetic Nephropathy Trial” (IDNT) in France and Belgium**. Presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Rotterdam, The Netherlands, November, 2002.

Arvan ME, **Rodby R**: **Serum C-reactive protein levels are associated with KT/V in hemodialysis**. Presented at the National Kidney Foundation 2003 Clinical Meetings, April 2003, Dallas TX. Am J Kid Dis 2003;41:A14.

Palmer A, Annemans L, Roze S, Lamotte M, Lapuerta P, Gabriel S, Chen R, Carita P, Villadary I, **Rodby R**, de Zeeuw D, Parving H: **Irbesartan is projected to be cost saving and life saving in the French setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria**. Presented at the 6th Annual European Congress of ISPOR (the International Society for Pharmacoeconomics and Outcomes Research), 2003.

Huang Z, Zhang W, Ahuja A, **Rodby R**, Gao WR, Clark W: **Blood flow rate effects in high-dose pre-dilution CVVH**. Presented at the 21st Annual Meeting of the International Society of Blood Purification, September 2003.

Smitten A, **Rodby R**, Chen R: **The increasing prevalence of microalbuminuria in the United States: Data from the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and NHANES 1999-2000**. Presented at the 36th Annual Meeting of the American Society of Nephrology, November 2003, San Diego, CA. JASN 2003;14:682A.

Abstracts and Presentations (cont.):

Ahuja A, **Rodby R**, Huang A, Gao D, Zhang W, Clark W: **Effect of pre-dilution replacement fluid administration on solute clearances in high-volume hemofiltration (HF)**: Presented at the 36th Annual Meeting of the American Society of Nephrology, November 2003, San Diego, CA. JASN 2003;14:734A.

Zhang W, Huang Z, Ahuja A, **Rodby R**, Clark W, Gao D: **Blood flow rate effects in high-dose pre-dilution CVVH**. Presented at the 36th Annual Meeting of the American Society of Nephrology, November 2003, San Diego, CA. JASN 2003;14:742A.

Palmer A, Annemans L, Roze S, Lamotte M, Lapuerta P, Gabriel S, Chen R, Carita P, Villadary I, Villadary I, **Rodby R**, de Zeeuw D, Parving H: **Irbesartan is projected to be cost and life saving in the USA for treatment of patients with type II diabetes, hypertension and microalbuminuria**. Presented at the 36th Annual Meeting of the American Society of Nephrology, November 2003, San Diego, CA. JASN 2003;14:193A.

Rodby R, Smitten A, Simon T, Chen R and the Collaborative Study Group: **The potential US public health impact of irbesartan on the cost of ESRD in patients with type II diabetes, overt nephropathy and hypertension**. JASN 2003;14:814A.

Coyle D, Levin A, Muirhead N, Palmer A, Réne de Cotret P, Soroka S, Amin M, Chen R, Dupont D, Forte L, **Rodby R**: **Cost-effectiveness of irbesartan 300 mg given early or late in patients with type 2 diabetes, hypertension and renal disease**. Presented at the 2005 Annual Conference of the Canadian Association for Population Therapeutics, April 2005, Vancouver, Canada.

Palmer AJ, Chen R, Valentine WJ, Roze S, Gabriel S, Mehin N, Bregman B, **Rodby R**: **Cost-utility analysis in a USA setting of screening and optimized treatment of nephropathy in hypertensive patients with type 2 diabetes**. Submitted to the 8th Annual European Congress of ISPOR (the International Society for Pharmacoeconomics and Outcomes Research), 2005.

Coresh J, Stevens L, Greene T, Eggers P, Kusek J, Van Lente F, Zhang L, Schmidt C, Stark P, Rohde R, **Rodby R**, Levey A, for the Chronic Kidney Disease-Epidemiology Collaboration: **Comparison of GFR equations using serum cystatin and creatinine: A pooled analysis of 1706 individuals**. Presented at the 38th Annual Meeting of the American Society of Nephrology, November 2005, Philadelphia, PA. JASN 2005;F-FC144.

Sinsakul M, Sika M, **Rodby R**, Middleton J, Shyr Y, Harris R, Lewis J: **Effects of celecoxib on urinary protein excretion in diabetic nephropathy**. Submitted to the 38th Annual Meeting of the American Society of Nephrology, November, 2005. JASN 2005;PUB577.

Dierks O, Sinsakul M, **Rodby R**: **Development of irreversible renal failure with ifosfamide**. Submitted to the 38th Annual Meeting of the American Society of Nephrology, November, 2005. JASN 2005;PUB597.

Gashti C, Salcedo S, **Rodby R**: **Accelerated veno-venous hemofiltration (AVVH); an alternative modality for critically-ill patients requiring renal replacement therapy (RRT)**. Presented at the 39th Annual Meeting of the American Society of Nephrology, November, 2006, San Diego, CA. JASN 2006;17:107A.

**Abstracts and
Presentations (cont.):**

Greene T, Coresh J, Liang L, Beej G, Hamm L, Lewis J, **Rodby R**, Stevens L, Weir M, Schmid C, Levey A, for the CKD-EPI Study Group: **Effect of source population on the relationship of GFR estimates with “true GFR”**. Presented at the 39th Annual Meeting of the American Society of Nephrology, November 2006, San Diego, CA. JASN 2006;17:142A.

Sinsakul M, Sika M, **Rodby R**, Middleton J, Shyr Y, Clyne S, Lehrich R, Harris R, Lewis J: **Effects of celecoxib on urinary protein excretion in diabetic nephropathy**. Presented at the 39th Annual Meeting of the American Society of Nephrology, November 2006, San Diego, CA. JASN 2006;17:159A.

Wilke CT, Jolly M, Block JA, **Rodby RA**, Pickard AS: **Ability of SF-35 and EQ-5D to discriminate among disease activity levels in lupus**. Podium Presentation at the 12th Annual meeting of the International Society of Pharmacoeconomics Outcomes Research (ISPOR), May 2007, Arlington, VA.

Wilke CT, Jolly M, Khandelwal S, **Rodby RA**, Block JA, Pickard AS: **Understanding limitations of patient reported clinical outcomes in lupus**. Poster Presentation at the 12th Annual meeting of the International Society of Pharmacoeconomics Outcomes Research (ISPOR), May 2007, Arlington, VA.

Jolly M, Pickard AS, The LS, Wilke C, **Rodby R**, Block J: **Modification and preliminary validation of the lupus quality of life (LUPUSQOL) Index: US version**. Presented at the 14th Annual Meeting of the International Society or Quality of Life Research, October 2007, Toronto, Canada.

Jolly M, Pickard AS, Wilke C, Khandelwal S, **Rodby R**, Block J: **Effect of lupus on sexual health of women**. Presented at the 71st Annual meeting of the American College of Rheumatology, November 2007, Boston, MA.

Jolly M, Pickard AS, Wilke C, Khandelwal S, **Rodby R**, Fogg L, Block J: **Satisfaction with care and health status in lupus**. Presented at the 71st Annual meeting of the American College of Rheumatology, November 2007, Boston, MA.

Jolly M, Pickard AS, Mikolaitis R, Wilke C, Khandelwal S, **Rodby R**, Block J: **Disease activity, body image and health status in lupus**. Presented at the 71st Annual meeting of the American College of Rheumatology, November 2007, Boston, MA.

Jolly M, Pickard AS, Wilke C, Lin H-W, Khandelwal S, **Rodby R**, Block J: **Development and validation of a US specific patient reported outcome measure**. Poster presentation at the 71st Annual meeting of the American College of Rheumatology, November 2007, Boston, MA.

Kropp J, Sinsakul M, Butsch J, **Rodby R**: **Laparoscopy in the early diagnosis and management of sclerosing encapsulating peritonitis**. Poster presentation at the 40th Annual Meeting of the American Society of Nephrology, November 2007, San Francisco, CA. JASN 2007;18:473A.

**Abstracts and
Presentations (cont.):**

Jolly M, Pickard AS, Mikolaitis RA, Wilke CF, **Rodby R**, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori M, Wallace D, Weisman MH, Block JA: **The LupusPRO®: A disease-specific patient reported outcome measure for systemic lupus erythematosus in the U.S.A.** Presented at the Annual meeting of the American College of Rheumatology, October 2009, Philadelphia, PA.

Jolly M, Pickard AS, Mikolaitis RA, Wilke CF, **Rodby R**, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori M, Wallace D, Weisman MH, Block JA: **The LupusPRO®: A disease-specific patient reported outcome measure for systemic lupus erythematosus in the U.S.A.** Presented at the 9th International Congress on Systemic Lupus Erythematosus, June 2010, Vancouver, Canada.

Jolly M, Pickard AS, McElhone K, The LS, Mikolaitis RA, **Rodby R**, Sequeira W, Utset TO, Nicassio P, Ishimori M, Wallace D, Weisman MH, Block JA: **Disease specific patient reported outcome benchmarks for US Lupus patients: LupusPRO and LupusQoL-US.** Presented at the 9th International Congress on Systemic Lupus Erythematosus, June 2010, Vancouver, Canada.

Ix JH, Wassel CL, Stevens LA, Beck GJ, Froissart M, Navis G, **Rodby R**, Torres VE, Zhang Y, Greene T, Levey AS: **Equations to estimate creatinine excretion rate: The CKD epidemiology collaboration.** Poster presentation at the 43rd Annual Meeting of the American Society of Nephrology, November 2010, Denver, CO. JASN 2010;21:178A.

Jolly M, Pickard SA, **Rodby R**, Weisman M, Merrill J, Wallace D, Block JA: **Validation of the final lupusPRO-V1.7: Disease targeted patient reported outcome measure.** Presented at the Annual Meeting of the American College of Rheumatology, November 2010, Atlanta, GA.

Jolly M, Pickard SA, Block JA, Mikolaitis RA, **Rodby RA**, Fogg L, Sequeira W, Cash TF, Moldovan I, Katsaros EP, Nicassio EP, Ishimori ML, Kosinski M, Merrill JT, Weisman MH, Wallace DJ: **Validation of a patient-reported outcome measure for lupus patients: V1.6.** Presented at the Annual Meeting of the EULAR, May 2011, London, UK.

Shidham G, Perna A, Fine D, **Rodby R**, Remuzzi G, Rovin B, Hebert L: **Inaccuracy of the morning spot PC ratio in estimating 24-h proteinuria magnitude in individual patients with non-diabetic chronic kidney disease or lupus nephritis.** Poster presentation at the 46th Annual Meeting of the American Society of Nephrology, November 2012, San Diego, CA. JASN 2012;23:403A.

Hebert LA, Birmingham D, Shidham G, Fine D, **Rodby R**, Petri M, Hevert P, Rovin BH: **Spot urine protein/creatinine ratio is more unreliable in estimating proteinuria in lupus nephritis than in other forms of chronic glomerular diseases.** Poster presentation at 47th Annual Meeting of the American Society of Nephrology, November 2012, Atlanta, GA. JASN 2013;24:792A

Gashti CN, **Rodby RA**: **Membrane therapeutic plasma exchange (mTPE): Early technical and clinical experience.** Poster presentation at 47th Annual Meeting of the American Society of Nephrology, November 2013, Atlanta, GA. JASN 2013;24:349A.

**Abstracts and
Presentations (cont.):**

Rodby R, Hsieh A, Niecestro R, Lewis J, Dwyer J, Umanath K, for the Collaborative Study Group: **Phosphorus binding with ferric citrate reduces managed care costs through reduced use of iron and erythropoiesis-stimulating agents (ESAs)**. Poster presentation and Bronze medal award at the 26th Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), April 2014, Tampa, FL. *J Manage Care Pharm* 2014;20:S53.

Rodby R, Umanath K, Niecestro R, Jackson J, Dwyer J, Lewis J, for the Collaborative Study Group: **Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs**. Poster presentation at the 2014 NKF Spring Clinical Meetings, April 2014, Las Vegas, NV. *Amer J Kid Dis* 2014;63:A118.

Rodby R, Umanath K, Hsieh A, Niecestro R, Lewis J, Dwyer J, for the Collaborative Study Group: **Phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD**. Poster presentation at the 2014 NKF Spring Clinical Meetings, April 2014, Las Vegas, NV. *Amer J Kid Dis* 2014;63:A95.

Sahota S, **Rodby R**: **In-patient hemodialysis without heparin**. Poster presentation at the 2014 NKF Spring Clinical Meetings, April 2014, Las Vegas, NV. *Amer J Kid Dis* 2014;63:A96.

Rodby R, Niecestro R, Bond C, Sika M, Dwyer J, Lewis J, Umanath K for the Collaborative Study Group: **Phosphorus binding with ferric citrate is associated with reduced hospitalizations and costs for cardiac, gastrointestinal and infection-related causes**. Oral Presentation at the 48th Annual Meeting of the American Society of Nephrology, November 2014, Philadelphia, PA. *JASN* 2014;25:56A.

Dwyer J, Berl T, Greene T, Hunsicker L, Pohl M, **Rodby R**, Sika M, Tuttle K, Umanath K, Lewis EJ, Lewis J for the Collaborative Study Group. **The collaborative study group: A non-profit academic research organization dedicated to nephrology**. Poster Presentation at the 48th Annual Meeting of the American Society of Nephrology, November 2014, Philadelphia, PA.

Lallinger M, Sinsakul M, **Rodby R**. **Methylprednisolone for prednisone-resistant minimal change disease**. Poster presented at the 2015 NKF Spring Clinical Meetings, April 2015, Dallas, TX. *Amer J Kid Dis* 2015;65:A52.

Sivagnanam M, Pandya S, **Rodby R**. **A “sweet” case of acute renal failure secondary to intravenous immunoglobulin administration**. Poster Presentation at the 2016 Midwest Society of General Internal Medicine, September 2016 Cleveland, OH.

Umanath K, Berl T, Greene T, Middleton JP, Concepcion BP, Pohl MA, Raz I, **Rodby RA**, Zidan M, Niecestro R, Sika M, Tuttle KR, Jacobson H, Lewis, EJ, Lewis JB, Dwyer JP, for the Collaborative Study Group. **The Collaborative Study Group: A Non-Profit Academic Research Organization Dedicated to Nephrology** Poster Presentation at the 50th Annual Meeting of the American Society of Nephrology, November 2016, Chicago, IL.